Nutritional therapies in Parkinson's disease

Current Treatment Options in Neurology

Volumn 9, Issue 3, 2007, Pages 198-204

  Evatt, Marian L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOHYDRATE; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; ISONIAZID; LEVODOPA; MUCUNA PRURIENS EXTRACT; NON PRESCRIPTION DRUG; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLANT EXTRACT; PROTEIN; PYRIDOXINE; RETINOL; TEGASEROD; TETRAHYDROLIPSTATIN; TRACE ELEMENT; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP; VITAMIN D;

ABDOMINAL PAIN; ANAMNESIS; ANTHROPOMETRIC PARAMETERS; ATAXIA; BARIUM MEAL; BODY HEIGHT; BODY WEIGHT; BONE PAIN; CAREGIVER; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY FIBER; DIETITIAN; DISEASE COURSE; DISEASE PREDISPOSITION; DIZZINESS; DRUG ABSORPTION; DRUG MEGADOSE; DRUG METABOLISM; DYSPHAGIA; FLATULENCE; FLUID INTAKE; FOOD INTAKE; HEADACHE; HEARTBURN; HUMAN; LIMB PAIN; MACRONUTRIENT; MALNUTRITION; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NUTRITIONAL REQUIREMENT; NUTRITIONAL SUPPORT; PARESTHESIA; PARKINSON DISEASE; PATIENT COUNSELING; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERIPHERAL NEUROPATHY; PROTEIN INTAKE; REVIEW; SPEECH THERAPY; STOMACH DISCOMFORT; TASTE DISORDER; VICIA FABA; VOMITING; WEAKNESS;

EID: 34248381286     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938409     Document Type: Review

References (59)

1. Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744-1754.
2. Olanow CW, Jankovic J: Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005, 20(Suppl 11):S3-S10.
3. VanItallie TB, Nonas C, Di Rocco A, et al.: Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005, 64:728-730.
4. Apaydin H, Ertan S, Ozekmekci S: Broad bean (Vicia faba) - a natural source of L-dopa - prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations. Mov Disord 2000, 15:164-166.
5. Rabey JM, Vered Y, Shabtai H, et al.: Broad bean (Vicia faba) consumption and Parkinson's disease. Adv Neurol 1993, 60:681-684.
6. Rabey JM, Vered Y, Shabtai H, et al.: Improvement of parkinsonian features correlates with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 1992, 55:725-727.
7. Ladha SS, Walker R, Shill HA: Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance. Mov Disord 2005, 20:630-631.
8. Manyam BV, Sanchez-Ramos JR: Traditional and complementary therapies in Parkinson's disease. Adv Neurol 1999, 80:565-574.
9. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group. J Altern Complement Med 1995, 1:249-255.
10. Katzenschlager R, Evans A, Manson A, et al.: Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004, 75:1672-1677.
11. Mena I, Cotzias GC: Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975, 292:181-184.
12. Pincus JH, Barry KM: Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987, 44:1006-1009.
13. Pincus JH, Barry K: Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987, 44:270-272.
14. Pincus JH, Barry KM: Dietary method for reducing fluctuations in Parkinson's disease. Yale J Biol Med 1987, 60:133-137.
15. Pincus JH, Barry K: Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology 1988, 38:481-483.
16. Karstaedt PJ, Pincus JH: Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992, 49:149-151.
17. Pare S, Barr SI, Ross SE: Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients. Am J Clin Nutr 1992, 55:701-707.
18. Berry EM, Growdon JH, Wurtman JJ, et al.: A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991, 41:1295-1297.
19. Baruzzi A, Contin M, Riva R, et al.: Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987, 10:527-537.
20. Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I: On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv Neurol 1983, 37:51-60.
21. Tan EK, Cheah SY, Fook-Chong S, et al.: Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005, 137:1-4.
22. Djaldetti R, Baron J, Ziv I, Melamed E: Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996, 46:1051-1054.
23. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003, 2:107-116.
24. Gustafsson K, Ekblad J, Sidenvall B: Older women and dietary advice: occurrence, comprehension and compliance. J Hum Nutr Diet 2005, 18:453-460.
25. Ueki A, Otsuka M: Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004, 251(Suppl 7):vII18-vII23.
26. Drost J, Harris LA: Diagnosis and management of chronic constipation. JAAPA 2006, 19:24-29.
27. Holick MF: The vitamin D epidemic and its health consequences. J Nutr 2005, 135:2739S-2748S.
28. Lorefat B, Ganowiak W, Wissing U, et al.: Food habits and intake of nutrients in elderly patients with Parkinson's disease. Gerontology 2006, 52:160-168.
29. Uc EY, Struck LK, Rodnitzky RL, et al.: Predictors of weight loss in Parkinson's disease. Mov Disord 2006, 21:930-936.
30. Mamhidir AG, Ljunggren G, Kihlgren M, et al.: Underweight, weight loss and related risk factors among older adults in sheltered housing - a Swedish follow-up study. J Nutr Health Aging 2006, 10:255-262.
31. Lorefalt B, Granerus AK, Unosson M: Avoidance of solid food in weight losing older patients with Parkinson's disease. J Clin Nurs 2006, 15:1404-1412.
32. Kashihara K: Weight loss in Parkinson's disease. J Neurol 2006, 253(Suppl 7):vii38-vii41.
33. Bachmann CG, Trenkwalder C: Body weight in patients with Parkinson's disease. Mov Disord 2006, 21:1824-1830.
34. Lorefalt B, Ganowiak W, Palhagen S, et al.: Factors of importance for weight loss in elderly patients with Parkinson's disease. Acta Neurol Stand 2004, 110:180-187.
35. Sienkiewicz-Jarosz H, Scinska A, Kuran W, et al.: Taste responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2005, 76:40-46.
36. D'Amelio M, Ragonese P, Morgante L, et al.: Long-term survival of Parkinson's disease: a population-based study. J Neurol 2006, 253:33-37.
37. Hellenbrand W, Seidler A, Boeing H, et al.: Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996, 47:636-643.
38. Ondo WG, Ben-Aire L, Jankovic J, et al.: Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand 2000, 101:79-84.
39. Nirenberg MJ, Waters C: Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006, 21:524-529.
40. Wolfrath SC, Borenstein AR, Schwartz S, et al.: Use of nutritional supplements in Parkinson's disease patients. Mov Disord 2006, 21:1098-1101.
41. Rajendran PR, Thompson RE, Reich SG: The use of alternative therapies by patients with Parkinson's disease. Neurology 2001, 57:790-794.
42. Suchowersky O, Gronseth G, Perlmutter J, et al.: Practice parameter: neuroprotective strategies and alternative therapies for Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:976-982.
43. Ishihara L, Brayne C: A systematic review of nutritional risk factors of Parkinson's disease. Nutr Res Rev 2005, 18:259-282.
44. Etminan M, Gill SS, Samii A: Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol 2005, 4:362-365.
45. Morens DM, Grandinetti A, Waslien CI, et al.: Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology 1996, 46:1270-1274.
46. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989, 46:1052-1060.
47. Fahn S: An open trial of high-dosage antioxidants in early Parkinson's disease. Am J Clin Nutr 1991, 53:380S-382S.
48. Fahn S: A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992, 32(Suppl):S128-S132.
49. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
50. Shults CW, Oakes D, Kieburtz K, et al.: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002, 59:1541-1550.
51. Postuma RB, Espay AJ, Zadikoff C, et al.: Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006, 66:1941-1943.
52. Hassin-Baer S, Cohen O, Vakil E, et al.: Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006, 29:305-311.
53. Todorovic Z, Dzoljic E, Novakovic I, et al.: Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006, 248:56-61.
54. Sato Y, Iwamoto J, Kanoko T, Satoh K: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005, 118:1250-1255.
55. Nakayama Y, Washio M, Mori M: Oral health conditions in patients with Parkinson's disease. J Epidemiol 2004, 14:143-150.
56. Schwarz J, Heimhilger E, Storch A: Increased periodontal pathology in Parkinson's disease. J Neurol 2006, 253:608-611.
57. Hathcock JN, Shao A: Risk assessment for coenzyme Q10 (ubiquinone). Regul Toxicol Pharmacol 2006, 45:282-288.
58. Lheureux P, Penaloza A, Gris M: Pyridoxine in clinical toxicology: a review. Eur J Emerg Med 2005, 12:78-85.
59. Callahan CM, Buchanan NN, Stump TE: Healthcare costs associated with percutaneous endoscopic gastrostomy among older adults in a defined community. J Am Geriatr Soc 2001, 49:1525-1529.